Monitor this situation.
Unsubscribe anytime.
[SITUATION] · [ACTIVE] · [BUSINESS]
2 clusters · 2 sources · 14 days · First seen · Last updated
Semaglutide market developments in Brazil and Spain
Overview
Developments regarding semaglutide treatments have emerged in Brazil and Spain. In Brazil, Dr Reddy’s Laboratories secured marketing authorization from the National Health Surveillance Agency (ANVISA) to sell a generic version of the medication in 2 mg and 4 mg doses. This follows a previous regulatory denial in April. The company intends to launch the product in collaboration with Aché to target the Brazilian diabetes market.
In Spain, Novo Nordisk introduced a new 2 mg weekly dose of Ozempic. This dosage is funded by the Spanish National Health System for treating adults with type 2 diabetes. Medical specialists noted that the higher dose provides increased efficacy in glycemic control and weight management for patients who do not meet metabolic targets on the 1 mg dose.
Entities
Novo Nordisk · Brazil · Spain · Aché · Dr Reddy’s Laboratories
Timeline
-
[HEALTH] 2 sourcesNovo Nordisk launches 2 mg Ozempic dose in Spain
A new 2 mg weekly dose of Ozempic is now available in Spain for adults with type 2 diabetes, offering improved glycemic control and weight reduction compared to the 1 mg dose.
-
[BUSINESS] 5 sourcesDr Reddy’s Laboratories receives Brazil approval for generic Ozempic
Dr Reddy’s Laboratories has obtained regulatory approval from Brazil’s ANVISA to market a generic version of semaglutide for type 2 diabetes treatment.
Sources
immedicohospitalario.es · lacronicadebadajoz.elperiodicoextremadura.com